BioMarin Pharmaceutical, Inc. (BMRN)

Evaluation: Based on all recent filings, financial statements, and news.

See full evaluation
Company performance

Current Price

as of Jan 06, 2025

$67.07

P/E Ratio

40.38

Market Cap

$12.78B

Loading...
Description

BioMarin Pharmaceutical, Inc. engages in the development and commercialization of therapies for people with serious and life-threatening rare diseases and medical conditions. Its pipeline products include Valoctocogene roxaparvovec, Vosoritide, and BMN 307. The company was founded by John C. Klock, Christopher M. Starr and Grant W. Denison on March 21, 1997, and is headquartered in San Rafael, CA.

Metrics

Overview

  • HQSan Rafael, CA
  • SectorHealth Technology
  • IndustryBiotechnology
  • TickerBMRN
  • Price$67.07+0.36%

Trading Information

  • Market cap$12.78B
  • Float98.76%
  • Average Daily Volume (1m)1,221,117
  • Average Daily Volume (3m)1,420,644
  • EPS$1.70

Company

  • Revenue$2.75B
  • Rev growth (1yr)26.69%
  • Net income$106.08M
  • Gross margin73.94%
  • EBITDA margin23.31%
  • EBITDA$173.06M
  • EV$13.54B
  • EV/Revenue4.93
  • P/E40.38
  • P/S4.81
  • P/B2.36
Documents